Low-Dose Colchicine for Cardiovascular Prevention

TL;DR: Heart disease is driven by more than cholesterol; inflammation in the artery wall plays its own part. Low-dose colchicine (0.5 mg a day) is an old, inexpensive anti-inflammatory that lowers that inflammation, and in two randomized trials it reduced cardiovascular events in people with established coronary disease, which led to FDA approval in 2023. The caveat worth stating is that the largest and most recent trial, in 2025, found no benefit after a heart attack, so enthusiasm has cooled and the evidence is mixed. It is a selective add-on for people who already have coronary disease and remain at risk despite good cholesterol control, rather than a drug for primary prevention or general longevity. It also carries meaningful drug interactions, so it belongs in a careful conversation with your physician.

What is low-dose colchicine, and why is it used for the heart?

Colchicine is one of the oldest medicines still in use, drawn from the autumn crocus and known for centuries as a treatment for gout. What is newer is the idea of using a small daily dose, 0.5 milligrams, to protect the heart. To see why that makes sense, it helps to know that heart disease is more than a cholesterol problem. Cholesterol, measured best as ApoB, builds the plaque in your arteries, but inflammation in the artery wall is what makes that plaque unstable and prone to rupture, which is what causes most heart attacks. You can lower cholesterol well and still carry inflammation-driven risk, often called residual inflammatory risk, and a simple blood test, high-sensitivity CRP, is one way to see it.

Colchicine works on that inflammation. It dampens the activity of neutrophils, a type of immune cell, and calms a specific alarm system inside cells called the NLRP3 inflammasome, which lowers the inflammatory signals that keep plaque inflamed. The proof that inflammation itself is a target came from the CANTOS trial, which used a powerful injectable antibody to lower inflammation and cut cardiovascular events without changing cholesterol at all.¹ That was a landmark finding, though the antibody was expensive and raised the risk of serious infection, so it never became a practical therapy. Colchicine is the cheap, oral way to test the same idea.

What does the evidence show?

Two randomized trials put low-dose colchicine on the map. COLCOT enrolled about 4,700 people soon after a heart attack and found that colchicine 0.5 mg daily reduced a composite of cardiovascular events by 23% compared with placebo over roughly two years.² LoDoCo2 tested the same dose in about 5,500 people with chronic, stable coronary disease and found an even larger reduction, roughly 31%.³ An earlier, smaller pilot pointed the same way.⁴ On the strength of those results, the FDA approved low-dose colchicine in 2023 as the first anti-inflammatory drug cleared to lower cardiovascular risk, for people with established atherosclerotic disease or multiple risk factors.⁵

Two caveats travel with those numbers. The reductions are relative, so the change in absolute terms is more modest, and neither trial showed that colchicine helps people live longer, only that it lowered the rate of cardiovascular events. Still, for a cheap generic pill, lowering the rate of heart attacks and strokes was a meaningful result.

Why did the newest, largest trial find no benefit?

In late 2024, and published in 2025, the largest colchicine heart trial yet, CLEAR SYNERGY, complicated the story. It enrolled about 7,000 people after a heart attack and found no benefit at all: the rate of cardiovascular events was 9.1% on colchicine and 9.3% on placebo, a hazard ratio of 0.99.⁶ Colchicine still lowered CRP, so it was doing its anti-inflammatory job, but that did not translate into fewer events in this group.

Why the disagreement with the earlier trials? A few reasons are debated. CLEAR SYNERGY studied people right after a heart attack, almost all treated with modern stents, a setting that differs from LoDoCo2's stable, chronic patients. The trial ran through the COVID era, which disrupted many studies. And it is simply the largest and most rigorous trial, which some experts read as a sign that the earlier enthusiasm ran ahead of the evidence. Pooled analyses that combine all the trials, including CLEAR SYNERGY, still show a net benefit, around a 25% reduction, but the newest large trial has clearly tempered how confidently anyone can promise colchicine will help.⁷

There is one reassuring wrinkle. LoDoCo2 had shown a small, unexplained increase in deaths from non-cardiovascular causes, which raised a safety question. CLEAR SYNERGY did not repeat that signal, and if anything pointed the other way, so the concern now looks like chance rather than a true harm.

Who is low-dose colchicine for, and who is it not for?

This is where the balance matters. Low-dose colchicine is a selective add-on rather than a foundation. The people most likely to be offered it are those who already have established coronary or atherosclerotic disease, are already on the proven basics like a statin and often aspirin, and who still carry risk, sometimes signaled by a stubbornly elevated high-sensitivity CRP. For that person, guidelines now list colchicine as an option to consider, a weak or optional recommendation rather than a must.⁸

It is not a primary-prevention drug. There is no good evidence that it helps people who do not yet have heart disease, and it should not be thought of as a general longevity pill. The foundations still do the heavy lifting: lowering ApoB, controlling blood pressure, not smoking, sleep, strength, and cardiometabolic health. Colchicine is a targeted addition for a specific, higher-risk situation, considered case by case.

How is it dosed, and what are the risks and interactions?

The cardiovascular dose is 0.5 milligrams once a day, which is lower and steadier than the pulsed dosing used for a gout flare. The most common side effect is stomach upset, above all diarrhea, which tends to show up early and often settles.

The interactions are where colchicine demands respect, and why it is a prescription conversation rather than a supplement you add on your own.

• Kidney and liver. Colchicine is cleared by the kidneys, so it is avoided in severe kidney impairment and in severe liver disease, and both candidacy and dose depend on kidney function.
• Certain other drugs. Colchicine is processed by a pathway called CYP3A4 and moved by a transporter called P-glycoprotein. Medicines that block those, including some antibiotics such as clarithromycin, can push colchicine to dangerous, even fatal levels, so those combinations are avoided. Grapefruit does the same thing on a smaller scale and is worth avoiding.
• Statins. Both colchicine and statins can, rarely, irritate muscle, so the combination slightly raises the risk of muscle injury, though most people tolerate it well.
• Pregnancy and breastfeeding. Colchicine crosses to the baby, so its use there is a careful, shared decision rather than routine.

None of this makes colchicine dangerous in the right hands. It makes it a medicine to use deliberately, with a physician who checks your kidney function and your medication list first.

Guidance from the Clinic

"Inflammation is the part of heart disease we used to watch and could not treat, so I am glad we now have a cheap pill that touches it. But I hold it in perspective. The two positive trials were encouraging, the newest and largest one was a letdown, and the truth sits in between. When I think about colchicine, it is for a specific patient: someone who already has coronary disease, whose ApoB and blood pressure are handled, and whose inflammation, often a high CRP, is still telling me they are at risk. For that person it is a reasonable add-on we decide on together, after I check their kidneys and their medication list. It is never the first move, and it is never a substitute for the basics that do most of the work."

Related at Fishtown Medicine

• What Is a Preventive Cardiologist? - the decision layer around therapies like this
• ApoB and Heart Health - the cholesterol target that comes first
• Beyond Statins: Other Ways to Lower Cholesterol and ApoB - the lipid side of the same plan
• High CRP: What It Means - the inflammation marker behind residual risk
• Stroke Prevention in Philadelphia - where colchicine fits in a broader plan

Scientific References

1. Ridker PM, Everett BM, Thuren T, et al. "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease." New England Journal of Medicine. 2017;377(12):1119-1131.
2. Tardif JC, Kouz S, Waters DD, et al. "Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction." New England Journal of Medicine. 2019;381(26):2497-2505.
3. Nidorf SM, Fiolet ATL, Mosterd A, et al. "Colchicine in Patients with Chronic Coronary Disease." New England Journal of Medicine. 2020;383(19):1838-1847.
4. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. "Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease." Journal of the American College of Cardiology. 2013;61(4):404-410.
5. U.S. Food and Drug Administration. Approval of low-dose colchicine (Lodoco) to reduce cardiovascular risk in adults with established atherosclerotic disease or multiple risk factors. 2023.
6. Jolly SS, d'Entremont MA, Lee SF, et al. "Colchicine in Acute Myocardial Infarction." New England Journal of Medicine. 2025;392(7):633-642.
7. Samuel M, Berry C, Dubé MP, et al. "Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis." European Heart Journal. 2025;46(26):2552-2563.
8. European Society of Cardiology. "2023 ESC Guidelines for the Management of Acute Coronary Syndromes." European Heart Journal. 2023.